Pancreatic Cancer Test
Pancreatic Cancer
DevelopmentActive
Key Facts
About Mosaique Diagnostic
Mosaique Diagnostic is a pioneer in clinical proteomics, leveraging its unique CE-MS platform to decode disease-specific peptide patterns from urine. Its core focus is the early, non-invasive detection and monitoring of chronic diseases, primarily in nephrology, oncology, and cardiology, enabling personalized medicine approaches. The company has commercialized several diagnostic tests in Germany through its subsidiary and maintains an extensive global academic and industry collaboration network. Its technology is backed by a robust publication record and a large proprietary database of human urinary proteome data.
View full company profileOther Pancreatic Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Ampligen® (rintatolimod) | AIM ImmunoTech | Early Access Program |
| HBM9027 | Harbour BioMed | Phase 1 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| AHPBA IRE Registry | AngioDynamics | Post-Market Registry |
| SIMBs + Immunotherapy | Advanced Microbubbles | Pre-clinical |
| CLS-014 | CLS Therapeutics | Pre-clinical |
| SOMA Platform | Coherence Neuro | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Pritumumab (PTB) | Nascent Biotech | Phase II (Planned) |
| Iontophoretic System | Continuity Biosciences | Pre-clinical |
| Lixumistat (IM156) | ImmunoMet Therapeutics | Phase 1b |
| Electron IORT | Intraop Medical | Approved |